Market capitalization | $18.39m |
Enterprise Value | $-8.52m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 0.20 |
P/B ratio (TTM) P/B ratio | 0.74 |
Dividend yield | 0.00% |
Last dividend (FY24) | $1.75 |
Revenue growth (TTM) Revenue growth | -100.00% |
Revenue (TTM) Revenue | $0.00 |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
3 Analysts have issued a MEI Pharma, Inc. forecast:
3 Analysts have issued a MEI Pharma, Inc. forecast:
Sep '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.66 -0.66 |
101%
101%
|
|
EBITDA | -38 -38 |
197%
197%
|
EBIT (Operating Income) EBIT | -38 -38 |
204%
204%
|
Net Profit | -47 -47 |
213%
213%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
MEI Pharma, Inc. engages in the clinical development of therapies for cancer. Its drug candidates includes Pracinostat, an oral HDAC inhibitor that is being developed in combination with azacitidine for the treatment of acute myeloid leukemia and myelodysplastic syndrome. Its pipeline also consists of ME-401, an oral PI3K delta inhibitor; Voruciclib, an oral CDK inhibitor; and ME-344, a mitochondrial inhibitor. The company was founded on December 1, 2000 and is headquartered in San Diego, CA.
Head office | United States |
CEO | Justin File |
Employees | 28 |
Founded | 2000 |
Website | www.meipharma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.